FREEDOM-C Trial Of Oral Treprostinil In Pulmonary Arterial Hypertension Fails To Meet Primary Endpoint United Therapeutics Corporation (Nasdaq: UTHR) announced the results of the FREEDOM-C trial of oral treprostinil, a sustained-release formulation of treprostinil, in pulmonary arterial hypertension (PAH). Preliminary analysis demonstrates that the trial did not achieve statistical significance for the primary endpoint, six minute walk (6MW) distance at Week 16.
Source: www.medicalnewstoday.com
# posted by Network @ 6:00 AM
